NEW ORLEANS -- Off-label use of oral elagolix (Orilissa) may be a more patient-friendly alternative to standard-of-care injectable GnRH antagonists for ovulation suppression during in vitro ...

Two Sealed Airtight Medical Vials Against Bright Background Front View. Real-world data conflict with a recent meta-analysis including patients from highly selected clinical trial populations.

Use of a gonadotropin-releasing hormone antagonist is associated with lower risks for death than GnRH agonists, a systematic review and meta-analysis found. Use of degarelix, a gonadotropin-releasing ...

Gonadotropin-releasing hormone (GnRH) therapy improves cognitive function in Down syndrome (DS) mouse models and male patients with DS, according to a new study. The findings reveal a previously ...

Mechanism of action. The efficacy of a GnRH agonist in the treatment of PMS depends on its ability to cause pituitary desensitization to GnRH. Depending on the potency of the agonist, the ...

Reports suggest that at least 25% of ovarian disorders are due to dysfunction of the brain mechanism in the hypothalamus that controls the gonadotropin-releasing hormone (GnRH), which is a molecule ...

Please provide your email address to receive an email when new articles are posted on . “Many transgender boys do not want to compromise their adult height,” Sabine E. Hannema, MD, PhD, a pediatric ...

Credit: Getty Images. Real-world data conflict with a recent meta-analysis including patients from highly selected clinical trial populations. Although a recent meta-analysis suggested that ...